Abstract
We studied 26 patients in a randomized, placebo-controlled, double-blind parallel trial to evaluate the efficacy and safety of donepezil in chronic poststroke aphasia. Donepezil (10 mg/day) improved aphasia severity at endpoint (week 16) relative to placebo (p = 0.037).
Publication types
-
Randomized Controlled Trial
MeSH terms
-
Acetylcholine / metabolism
-
Adult
-
Aphasia / drug therapy*
-
Aphasia / etiology*
-
Aphasia / physiopathology
-
Brain / blood supply
-
Brain / drug effects
-
Brain / physiopathology
-
Cerebrovascular Circulation / drug effects
-
Cerebrovascular Circulation / physiology
-
Donepezil
-
Double-Blind Method
-
Female
-
Humans
-
Indans / administration & dosage*
-
Language Tests
-
Male
-
Middle Aged
-
Nerve Regeneration / drug effects
-
Nerve Regeneration / physiology
-
Neural Pathways / blood supply
-
Neural Pathways / drug effects
-
Neural Pathways / physiopathology
-
Neuronal Plasticity / drug effects
-
Neuronal Plasticity / physiology
-
Nootropic Agents / administration & dosage
-
Piperidines / administration & dosage*
-
Placebos
-
Recovery of Function / drug effects
-
Recovery of Function / physiology
-
Speech Therapy
-
Stroke / complications*
-
Stroke / physiopathology
-
Treatment Outcome
Substances
-
Indans
-
Nootropic Agents
-
Piperidines
-
Placebos
-
Donepezil
-
Acetylcholine